Drugs / Balinatunfib
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07272629 | Dec 2025 → May 2026 | — | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT05844735 | May → Oct 2023 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT05858788 | May → Jul 2023 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT05453942 | Jul 2022 → Feb 2023 | psoriasis | Sanofi | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT07222189 | May 2026 → May 2030 expected | Crohn disease, ulcerative colitis | Sanofi | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT06867094 | Mar 2025 → Jul 2027 expected | ulcerative colitis | Sanofi | Recruiting | No outcome recorded |
| Phase 2 | NCT06637631 | Dec 2024 → Jul 2027 expected | Crohn disease | Sanofi | Recruiting | No outcome recorded |
| Phase 2 | NCT06073093 | Nov 2023 → Jun 2025 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT06073119 | Oct 2023 → Nov 2024 | psoriasis | Sanofi | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | balinatunfib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07222189 ↗ |
| Known as | SAR441566 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06073093 ↗ |
| Modality | Small molecule | — CHEMBL6068043 ↗ |
| Route | Oral | “4-week oral treatment with SAR441566” NCT05453942 ↗ |